Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-23.36M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.07 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -291924.97% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | 10.91% |
| Return on Assets (Trailing 12 Months) | 7.47% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.92 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.70M |
| Free Float | 11.34M |
| Market Capitalization | $14.03M |
| Average Volume (Last 20 Days) | 7659.95 |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 63.40% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |